151389-25-2

Basic information

• Product Name: 2-PIPERIDIN-4-YLPYRIMIDINE
• Synonyms: 2-PIPERIDIN-4-YLPYRIMIDINE
• CAS NO: 151389-25-2
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.2196
• Mol File: 151389-25-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 271.867 °C at 760 mmHg
• Flash Point: 118.221 °C
• Appearance: /
• Density: 1.066 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.526
• PKA: 9.97±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERIDIN-4-YLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERIDIN-4-YLPYRIMIDINE(151389-25-2)
• EPA Substance Registry System: 2-PIPERIDIN-4-YLPYRIMIDINE(151389-25-2)

Safety Data

• Hazardous Substances Data: 151389-25-2(Hazardous Substances Data)

Usage

General Description

2-PIPERIDIN-4-YLPYRIMIDINE, also known as P4P, is a chemical compound with a molecular formula C10H14N4. It is a pyrimidine derivative that contains a piperidine ring as a substituent. P4P has been studied for its potential pharmaceutical and biological activities, particularly as an anticancer agent and a modulator of immune response. It has also been investigated for its potential use in the treatment of various diseases and conditions. 2-PIPERIDIN-4-YLPYRIMIDINE has garnered interest in the scientific community due to its diverse biological properties and potential therapeutic applications. However, further research is needed to fully understand its pharmacological properties and potential medical uses.

InChI:InChI=1/C9H13N3/c1-4-11-9(12-5-1)8-2-6-10-7-3-8/h1,4-5,8,10H,2-3,6-7H2

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 182416-02-0 4-hydroxy-4-pyrimidin-2-yl-piperidine-1-carboxylic acid tert-butyl ester 
• 182416-03-1 N-t-butoxycarbonyl-4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine 
• 182416-05-3 tert-butyl 4-(pyrimidin-2-yl)piperidine-1-carboxylate 

Relevant articles and documents

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D 2 and α1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]- 1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.

PROLINE DERIVATIVES AND USE THEREOF AS DRUGS

The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.